BaselArea.swiss assisted Roivant Sciences and its affiliated companies in evaluating and relocating to the site. The business location promotion organisation for northwest Switzerland welcomes the new companies to the region and is pleased that such exciting and fast-growing companies chose Basel for their headquarters.
"Roivant's mission is to reduce the time and cost of developing new medicines for patients," said Vivek Ramaswamy, founder of the Roivant group of companies, in a statement announcing the new global headquarters in Basel.
"We believe this location in the hub of European pharmaceutical innovation and talent will support our vision."
The global bipharmaceutical company pursues innovative drug development, collaborating closely with major industry players such as Eisai, GlaxoSmithKline and Takeda Pharmaceuticals. Roivant has wholly-or majority-owned subsidiary companies focused on neurology, dermatology, urology, endocrinology, women's health, and rare diseases.
Several Roivant Sciences affiliates have opened their headquarters in Basel simultaneously, according to the statement. One of them is Axovant Sciences Ltd., a clinical-stage biopharmaceutical company focused on the treatment of dementia.
From its new headquarters in Basel, Axovant Sciences intends to “build a fully integrated organization to manage global commercial and medical strategies, manufacturing and supply chain, intellectual property, and other business functions,” said Mark Altmeyer, President and Chief Commercial Officer of Axovant Sciences.
“Our presence in Basel will provide access to a high-quality talent pool that will be key to our future success."